Sequence and Time-of-day Infusion of immunoCHemotherapy Affect Response in Oesophageal Cancer in the NeOadjuvant Setting

Guangdong Provincial People's Hospital350 enrolled

Overview

It is reported that compared to chemotherapy alone, immunochemotherapy has significantly improved the overall survival of patients with advanced metastatic ESCC. However, there are still more than 30% of patients who cannot benefit from this treatment modality. In addition to these factors, the time-of-day infusion and administration sequence of immunochemotherapy have been reported to be associated with tumor responses and overall survival. In this study, The investigators aimed to explore the roles of infusion time and administration sequence of immunochemotherapy in predicting tumor responses and overall survival in patients with advanced ESCC.

Study Type

OBSERVATIONAL

Enrollment

350

Conditions

Esophagus Cancer

Eligibility

Sex: ALLMin age: 18 YearsMax age: 78 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Pathologically diagnosed as esophageal squamous cell carcinoma * KPS≥80 * Adequate organ function * No distant metastasis * The diseases could be resected or potentially resectable after immunochemotherapy assessed by a thoracic oncologist Exclusion Criteria: * incomplete medical record which affects statistical analysis * have participated in previous interventional clinical trials * other situations evaluated by investigators not meet the enrollment

Locations (1)

Guangdong Provincial People's Hospital

Outcomes

Primary Outcomes

Overall survival

Overall survival rate

Time frame: from the date of diagnosis to the date of death, assessed up to 100 months

Secondary Outcomes

Pathologic complete response rate (pCR)

The rate of pathologic complete response rate after the combined treatment of chemotherapy and immunotherapy following surgery

Time frame: Three to five working days after surgery